Leadership Overview
Exelixis has 4 executives leading key functions including finance, clinical development, and operations.
Driven by a commitment to innovation, Exelixis focuses on discovering, developing, and commercializing new medicines for difficult-to-treat cancers, aiming to improve patient outcomes and expand treatment options globally.
Driven by a commitment to innovation, Exelixis focuses on discovering, developing, and commercializing new medicines for difficult-to-treat cancers, aiming to improve patient outcomes and expand treatment options globally.
Leadership Roles at Exelixis
Gregorina Parah - Chief Financial Officer
Gregorina Parah, the Chief Financial Officer at Exelixis, directs the company's financial strategy and operations. Overseeing all fiscal activities, Parah ensures robust financial planning, accurate reporting, and effective resource allocation to support Exelixis's mission of developing new medicines for difficult-to-treat cancers. This leadership position involves managing budgets, forecasting financial performance, and maintaining strong relationships with investors and financial institutions. Parah's oversight extends to optimizing financial structures to facilitate the discovery, development, and commercialization of innovative oncology treatments. The Chief Financial Officer's role is critical in driving the company's growth and ensuring its long-term financial health, directly impacting the ability to bring life-changing therapies to patients in the United States and beyond. Gregorina Parah's expertise underpins the company's capacity to fund its extensive research and development pipeline.
Christopher Senner - Executive Vice President & Chief Financial Officer
Christopher Senner, the Executive Vice President & Chief Financial Officer at Exelixis, guides the company's comprehensive financial management and strategic fiscal planning. Senner's responsibilities encompass overseeing all financial operations, including accounting, treasury, and investor relations, ensuring alignment with Exelixis's objective to develop and commercialize novel oncology treatments. This executive role involves managing capital allocation, driving financial performance, and supporting the company's growth initiatives in the United States. The Executive Vice President & Chief Financial Officer plays a pivotal part in securing the financial resources necessary for the discovery and development of new medicines for challenging cancers. Christopher Senner's leadership ensures the financial integrity and strategic direction required to advance Exelixis's pipeline and expand market access for its therapeutic offerings, contributing significantly to the company's overall mission.
Craig Palmer - Senior Vice President, Chief of Staff
Craig Palmer, the Senior Vice President, Chief of Staff at Exelixis, provides strategic operational support and drives key initiatives across the organization. Palmer's role involves enhancing executive decision-making and ensuring efficient execution of company-wide strategies focused on the discovery, development, and commercialization of new oncology medicines. This leadership position facilitates cross-functional collaboration and streamlines operational processes to accelerate progress in bringing innovative treatments to patients. The Senior Vice President, Chief of Staff works closely with executive leadership to manage strategic projects and optimize resource deployment. Craig Palmer's contributions are essential in driving operational excellence and supporting the company's mission to address difficult-to-treat cancers, ensuring that Exelixis effectively advances its pipeline and market presence.
Carol O'Hear - Head Chief Medical Officer, Clinical Development
Carol O'Hear, the Head Chief Medical Officer, Clinical Development at Exelixis, directs the company's clinical research and development programs for novel oncology therapies. O'Hear leads the strategic design and execution of clinical trials, focusing on advancing Exelixis's pipeline of medicines for difficult-to-treat cancers. This critical role involves overseeing all phases of clinical development, ensuring patient safety, and generating robust data to support regulatory submissions and commercialization efforts in the United States. The Head Chief Medical Officer, Clinical Development collaborates closely with research, regulatory affairs, and commercial teams to translate scientific discoveries into effective patient treatments. Carol O'Hear's expertise is fundamental to Exelixis's mission of improving outcomes for cancer patients through innovative therapeutic solutions.
Explore Leadership Teams in Manufacturing
Baxter International is a global healthcare company that develops and manufactures medical devices, pharmaceuticals, and hospital care products. Its offerings include infusion systems, injectable therapies, surgical technologies, and patient monitoring solutions used by hospitals, clinics, and healthcare providers worldwide.
Company Leadership SW
OS
Founded in 1967, Douglas Pharmaceuticals is a manufacturer of pharmaceutical products. The company started out distributing prescription medicines, before manufacturing and later successfully researching and developing its products for export. The company is headquartered in Auckland, New Zealand.
Company Leadership SW
BL
CR
TB
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segments products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing,...
Company Leadership DK
KB
CD
21st Century Vitamins operates as a globally recognized manufacturer and distributor of dietary supplements, positioned within the broader health and wellness industry. The company, through its parent entity 21st Century HealthCare, Inc., focuses on developing, producing, and delivering a wide range of vitamins, minerals, herbal supplements, and specialty nutritional products designed to support everyday health and well-being. With a history spanning more than three decades, the organization has established itself as a trusted and accessible brand in the consumer healthcare market. At its core, the company functions as both a manufacturer and a direct-to-consumer wellness provider. It produces an extensive portfolio of dietary supplements that cater to diverse health needs, including general nutrition, immune support, cardiovascular health, digestive wellness, sports nutrition, and beauty supplements. Its offerings range from traditional multivitamins and single-nutrient formulations to advanced blends such as amino acids, probiotics, and plant-based supplements. This breadth of product categories reflects the companys strategy of addressing a wide spectrum of consumer health requirements through scientifically formulated solutions.
Company Leadership SS
FC
KW
Frequently Asked Questions Regarding Exelixis Top Executives and Leadership Team
Unlock more people and company data
